CJC-1295 with DACvsIGF-1

CJC-1295 with DAC shares the same core peptide sequence and GHRH receptor binding mechanism as the no-DAC version — it activates Gs/adenylyl cyclase/cAMP/PKA signaling in pituitary somatotrophs to stimulate GH synthesis and secretion. The critical difference is the Drug Affinity Complex (DAC), a reactive N-hydroxysuccinimide ester linker attached to the peptide that covalently and irreversibly binds to circulating serum albumin after injection.

Albumin is the most abundant plasma protein with a half-life of approximately 19 days. By permanently conjugating to albumin, the DAC moiety transforms CJC-1295 from a short-acting peptide (30-minute half-life) into a long-circulating molecule with a half-life of 6-8 days. The albumin-bound peptide continuously activates GHRH receptors as it circulates, producing a sustained elevation of GH levels rather than discrete pulses.

This sustained GH elevation is both the advantage and disadvantage of the DAC version. The convenience of weekly dosing is appealing, and total GH output over time may be higher. However, continuous GHRH receptor stimulation can lead to receptor desensitization (tachyphylaxis), and the loss of natural pulsatility may reduce the efficiency of GH signaling at target tissues. Somatostatin — the hypothalamic hormone that normally creates the troughs between GH pulses — is partially overridden by continuous receptor stimulation, which blunts the natural feedback regulation. Some practitioners also express concern that sustained GH elevation more closely mimics the pathological hormone profile of acromegaly than the healthy pulsatile pattern.

IGF-1 (Insulin-like Growth Factor 1) is a 70-amino-acid peptide hormone with approximately 50% structural homology to proinsulin. It is primarily produced by hepatocytes in response to growth hormone stimulation, though virtually all tissues produce IGF-1 locally for paracrine/autocrine signaling. Circulating IGF-1 is bound to six IGF binding proteins (IGFBP-1 through IGFBP-6), with approximately 80-90% bound to IGFBP-3 in a ternary complex with the acid-labile subunit (ALS). Only free, unbound IGF-1 (approximately 1-2% of total) can activate receptors.

IGF-1 binds to the IGF-1 receptor (IGF-1R), a heterotetrameric receptor tyrosine kinase structurally similar to the insulin receptor. Ligand binding triggers receptor autophosphorylation and recruitment of insulin receptor substrate (IRS) adaptor proteins, activating two major downstream cascades. The PI3K/Akt/mTOR pathway drives protein synthesis (through mTORC1 activation of S6K1 and inhibition of 4E-BP1), cell survival (through BAD phosphorylation and Bcl-2 family regulation), and glucose uptake (through GLUT4 translocation). The Ras/Raf/MEK/ERK pathway promotes cell proliferation, differentiation, and gene expression changes required for tissue growth.

In skeletal muscle, IGF-1's effects include both hypertrophy (enlargement of existing muscle fibers through increased protein synthesis) and hyperplasia (generation of new muscle cells through satellite cell activation and differentiation). Local muscle-derived IGF-1 isoforms (including the MGF splice variant) play a particularly important role in exercise-induced muscle adaptation. The very short half-life of free IGF-1 (10-20 minutes) means that therapeutic administration requires frequent dosing or modified forms (such as IGF-1 LR3 with its extended half-life). Native IGF-1 also binds the insulin receptor (with lower affinity), which contributes to its hypoglycemic effects — a significant clinical risk that requires careful glucose monitoring and administration with food.